Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer
2014 · Medical Oncology · 115 citations
https://doi.org/10.1007/s12032-014-0391-z
Y
Yunlang Cai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
55
Papers
1.1K
Citations
16
h-index
26
i10-index
Yunlang Cai is an academic researcher from Hunan Normal University. The author has contributed to research in topics: Cancer Research and Treatments & Endometriosis Research and Treatment & Ovarian cancer diagnosis and treatment. The author has an h-index of 16, co-authored 47 publications.
Papers by this author
worksPSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population
2016 · Scientific Reports · 15 citations
https://doi.org/10.1038/srep23465
CSF-1-induced DC-SIGN+ macrophages are present in the ovarian endometriosis
2022 · Reproductive Biology and Endocrinology · 7 citations
https://doi.org/10.1186/s12958-022-00901-w
ALTER-GO-010: A multicenter, single-arm, phase II study of anlotinib combined with carboplatin plus paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer
2025 · Gynecologic Oncology · 0 citations
https://doi.org/10.1016/j.ygyno.2025.04.360
2260eP AG/mFOLFIRINOX plus tislelizumab as first-line therapy for locally advanced/metastatic pancreatic ductal adenocarcinoma: A phase II clinical study
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2877
FIRST-LINE ANLOTINIB COMBINED WITH CARBOPLATIN/PACLITAXEL FOLLOWED BY ANLOTINIB MAINTENANCE THERAPY IN ADVANCED OVARIAN CANCER: PRELIMINARY EFFICACY AND SAFETY FROM ALTER-GO-010 PHASE II MULTICENTER TRIAL
2025 · International Journal of Gynecological Cancer · 0 citations
https://doi.org/10.1016/j.ijgc.2025.102258
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat